141 related articles for article (PubMed ID: 27258216)
1. Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers.
Kameswaran M; Pandey U; Gamre N; Vimalnath KV; Sarma HD; Dash A
Appl Radiat Isot; 2016 Aug; 114():196-201. PubMed ID: 27258216
[TBL] [Abstract][Full Text] [Related]
2. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of
Kameswaran M; Sarma HD; Dash A
Appl Radiat Isot; 2017 May; 123():109-113. PubMed ID: 28260607
[TBL] [Abstract][Full Text] [Related]
5. A systematic study on the utility of CHX-A''-DTPA-NCS and NOTA-NCS as bifunctional chelators for
Pandey U; Gamre N; Lohar SP; Dash A
Appl Radiat Isot; 2017 Sep; 127():1-6. PubMed ID: 28478331
[TBL] [Abstract][Full Text] [Related]
6. AAZTA
Klasen B; Moon ES; Rösch F
Nucl Med Biol; 2021; 96-97():80-93. PubMed ID: 33839678
[TBL] [Abstract][Full Text] [Related]
7. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
8. Preparation of
Kameswaran M; Pandey U; Gamre N; Sarma HD; Dash A
Appl Radiat Isot; 2019 Jun; 148():184-190. PubMed ID: 30974402
[TBL] [Abstract][Full Text] [Related]
9. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Fiedler L; Kellner M; Gosewisch A; Oos R; Böning G; Lindner S; Albert N; Bartenstein P; Reulen HJ; Zeidler R; Gildehaus FJ
Nucl Med Biol; 2018 May; 60():55-62. PubMed ID: 29571067
[TBL] [Abstract][Full Text] [Related]
11. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
Persson M; Tolmachev V; Andersson K; Gedda L; Sandström M; Carlsson J
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1457-62. PubMed ID: 16193312
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
13. Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate.
MacPherson DS; Hwang D; Sarrett SM; Keinänen O; Rodriguez C; Rader C; Zeglis BM
Mol Pharm; 2023 Jan; 20(1):775-782. PubMed ID: 36377696
[TBL] [Abstract][Full Text] [Related]
14. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.
Chakravarty R; Chakraborty S; Sarma HD; Nair KV; Rajeswari A; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):354-63. PubMed ID: 27264196
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.
Ray GL; Baidoo KE; Wong KJ; Williams M; Garmestani K; Brechbiel MW; Milenic DE
Br J Pharmacol; 2009 Aug; 157(8):1541-8. PubMed ID: 19681874
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Characterization of the
Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.
Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G
Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
